Karuna Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2009

Location

Boston MA US

Primary Industry

Biotechnology

About

Founded in 2009 and based in Massachusetts, the US, Karuna Therapeutics, Inc., formerly known as Karuna Pharmaceuticals Inc., develops therapeutics for psychosis and cognitive disorders across the central nervous system (CNS) such as schizophrenia and Alzheimer's Disease. The company is advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected neurological conditions through the cultivation of deep expertise in neuroscience, and inventive thinking around drug discovery and development. Andrew Miller is the founder of the company. In April 2019, the company raised USD 80 million in Series B funding from Sofinnova Investments, ARCH Venture Partners, and other investors. In March 2021, the firm became a public company with a total offering of USD 120.00 per share, under the ticker symbol NASDAQ: KRTX. The firm’s product KarXT targets the muscarinic acetylcholine receptors composed of xanomeline, a novel muscarinic acetylcholine receptor agonist (activator), and trospium chloride, a muscarinic receptor antagonist (blocker). The company generated USD 43.4 million in revenue in 2020. The company plans to advance KarXT into a Phase 2 clinical trial for the treatment of dementia-related psychosis in the first half of 2022.

Current Investors

ARCH Venture Partners, Wellcome Trust, PureTech Health plc

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.karunatx.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Timeline of Key Events

Want to see the Timeline of Key Events?

Request a demo for full access to this profile.

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin

31 Dec 2017

(5,500,000)

(6,000,000)

31 Dec 2018

(17,100,000)

(17,500,000)

31 Dec 2019

(45,405,000)

(45,347,000)

(43,957,000)

31 Dec 2020

(71,816,000)

(71,029,000)

(68,554,000)

31 Dec 2021

31 Dec 2022

31 Dec 2023

Unlock the recent years of financials and more for Karuna Therapeutics, Inc..

Request a demo to see more.

Employee Data

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.